blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1611133

EP1611133 - CONDENSED N-HETEROCYCLIC COMPOUND AND USE THEREOFF AS CRF RECEPTOR ANTAGONIST [Right-click to bookmark this link]
Former [2006/01]CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS
[2010/04]
StatusNo opposition filed within time limit
Status updated on  13.05.2011
Database last updated on 19.10.2024
Most recent event   Tooltip04.10.2013Lapse of the patent in a contracting state
New state(s): HU		published on 06.11.2013  [2013/45]
Applicant(s)For all designated states
SmithKline Beecham (Cork) Limited
Currabinny Carrigaline
Cork / IE
For all designated states
NEUROCRINE BIOSCIENCES, INC.
10555 Science Center Drive
San Diego, CA 92121 / US
[2008/45]
Former [2006/01]For all designated states
SB PHARMCO PUERTO RICO INC. CSC, The United States Corporation Company
105 Ponce de Leon Avenue, One Comptroller Plaza
00917 Hato Rey / PR
For all designated states
NEUROCRINE BIOSCIENCES, INC.
10555 Science Center Drive
San Diego, CA 92121 / US
Inventor(s)01 / Andreotti, Daniele, c/o GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
02 / Bernasconi, Giovanni, c/o GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
03 / Castiglioni, Emiliano, c/o GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
04 / Contini, Stefania, Anne c/o GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
05 / Di Fabio, Romano, c/o GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
06 / Fazzolari, Elettra, c/o GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
07 / Feriani, Aldo, c/o GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
08 / Gentile, Gabriella, c/o GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
09 / Mattioli, Mario, GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
10 / Mingardi, Anna, GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
11 / Sabbatini, Fabio, Maria, GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
12 / St-Denis, Yves, GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
 [2006/11]
Former [2006/01]01 / Andreotti, Daniele, c/o GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
02 / Bernasconi, Giovanni, c/o GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
03 / Castiglioni, Emiliano, c/o GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
04 / Contini, Stefania, c/o GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
05 / Di Fabio, Romano, c/o GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
06 / Fazzolari, Elettra, c/o GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
07 / Feriani, Aldo, c/o GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
08 / Gentile, Gabriella, c/o GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
09 / Mattioli, Mario, GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
10 / Mingardi, Anna, GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
11 / Sabbatini, Fabio, GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
12 / St-Denis, Yves, GlaxoSmithKline SpA
Via Alessandro Fleming 2
37100 Verona / IT
Representative(s)Dolton, Peter Irving Ernest
GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford, Middlesex TW8 9GS / GB
[N/P]
Former [2006/01]Dolton, Peter Irving Ernest
GlaxoSmithKline Corporate Intellectual Property (CN9.25.1) 980 Great West Road
Brentford, Middlesex TW8 9GS / GB
Application number, filing date04726237.307.04.2004
[2006/01]
WO2004IB01350
Priority number, dateGB2003000820809.04.2003         Original published format: GB 0308208
US20030485322P07.07.2003         Original published format: US 485322 P
[2006/01]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2004094420
Date:04.11.2004
Language:EN
[2004/45]
Type: A1 Application with search report 
No.:EP1611133
Date:04.01.2006
Language:EN
The application published by WIPO in one of the EPO official languages on 04.11.2004 takes the place of the publication of the European patent application.
[2006/01]
Type: B1 Patent specification 
No.:EP1611133
Date:07.07.2010
Language:EN
[2010/27]
Search report(s)International search report - published on:EP04.11.2004
ClassificationIPC:C07D471/04, C07D487/04
[2006/01]
CPC:
C07D471/04 (EP,KR,US); A61P1/02 (EP); A61P1/04 (EP);
A61P1/08 (EP); A61P1/14 (EP); A61P11/02 (EP);
A61P11/04 (EP); A61P11/06 (EP); A61P11/16 (EP);
A61P13/02 (EP); A61P13/10 (EP); A61P15/00 (EP);
A61P15/08 (EP); A61P17/00 (EP); A61P17/02 (EP);
A61P17/04 (EP); A61P17/06 (EP); A61P19/02 (EP);
A61P19/06 (EP); A61P19/08 (EP); A61P25/00 (EP);
A61P25/02 (EP); A61P25/04 (EP); A61P25/06 (EP);
A61P25/18 (EP); A61P25/20 (EP); A61P25/22 (EP);
A61P25/24 (EP); A61P25/28 (EP); A61P25/30 (EP);
A61P25/32 (EP); A61P25/34 (EP); A61P25/36 (EP);
A61P27/02 (EP); A61P27/16 (EP); A61P29/00 (EP);
A61P3/04 (EP); A61P3/08 (EP); A61P3/10 (EP);
A61P31/04 (EP); A61P31/16 (EP); A61P31/22 (EP);
A61P35/00 (EP); A61P37/02 (EP); A61P37/08 (EP);
A61P43/00 (EP); A61P5/00 (EP); A61P5/38 (EP);
A61P9/10 (EP); C07D403/14 (KR); C07D487/04 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2006/01]
Extension statesALNot yet paid
HR05.10.2005
LT05.10.2005
LV05.10.2005
MKNot yet paid
TitleGerman:KONDENSIERTE N-HETEROZYCLISCHE VERBINDUNG UND IHRE VERWENDUNG ALS CRF-REZEPTOR ANTAGONIST[2010/04]
English:CONDENSED N-HETEROCYCLIC COMPOUND AND USE THEREOFF AS CRF RECEPTOR ANTAGONIST[2010/04]
French:DERIVÉ N-HÉTÉROCYCLIQUE CONDENSÉ ET SONN UTILISATION EN TANT QUE ANTAGONISTE DU RÉCEPTEUR CRF[2010/04]
Former [2006/01]KONDENSIERTE N-HETEROZYCLISCHE VERBINDUNGEN UND IHRE VERWENDUNG ALS CRF-REZEPTOR ANTAGONISTEN.
Former [2006/01]CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS
Former [2006/01]DERIVES BICYCLIQUES, LEUR PREPARATION, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEUR USAGE THERAPEUTIQUE
Entry into regional phase05.10.2005National basic fee paid 
05.10.2005Designation fee(s) paid 
05.10.2005Examination fee paid 
Examination procedure09.02.2005Request for preliminary examination filed
International Preliminary Examining Authority: EP
05.10.2005Examination requested  [2006/01]
25.07.2007Despatch of a communication from the examining division (Time limit: M04)
22.11.2007Reply to a communication from the examining division
11.09.2008Despatch of a communication from the examining division (Time limit: M04)
24.12.2008Reply to a communication from the examining division
04.11.2009Despatch of a communication from the examining division (Time limit: M04)
03.12.2009Reply to a communication from the examining division
26.01.2010Communication of intention to grant the patent
25.05.2010Fee for grant paid
25.05.2010Fee for publishing/printing paid
Divisional application(s)EP08169936.5  / EP2186813
Opposition(s)08.04.2011No opposition filed within time limit [2011/24]
Fees paidRenewal fee
27.03.2006Renewal fee patent year 03
10.04.2007Renewal fee patent year 04
18.03.2008Renewal fee patent year 05
07.04.2009Renewal fee patent year 06
15.03.2010Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT07.07.2010
CY07.07.2010
CZ07.07.2010
DK07.07.2010
EE07.07.2010
FI07.07.2010
HU07.07.2010
NL07.07.2010
PL07.07.2010
RO07.07.2010
SE07.07.2010
SI07.07.2010
SK07.07.2010
TR07.07.2010
BG07.10.2010
GR08.10.2010
PT08.11.2010
IE07.04.2011
LU07.04.2011
[2013/45]
Former [2013/44]AT07.07.2010
CY07.07.2010
CZ07.07.2010
DK07.07.2010
EE07.07.2010
FI07.07.2010
NL07.07.2010
PL07.07.2010
RO07.07.2010
SE07.07.2010
SI07.07.2010
SK07.07.2010
TR07.07.2010
BG07.10.2010
GR08.10.2010
PT08.11.2010
IE07.04.2011
LU07.04.2011
Former [2013/25]AT07.07.2010
CY07.07.2010
CZ07.07.2010
DK07.07.2010
EE07.07.2010
FI07.07.2010
NL07.07.2010
PL07.07.2010
RO07.07.2010
SE07.07.2010
SI07.07.2010
SK07.07.2010
BG07.10.2010
GR08.10.2010
PT08.11.2010
IE07.04.2011
LU07.04.2011
Former [2012/20]AT07.07.2010
CY07.07.2010
CZ07.07.2010
DK07.07.2010
EE07.07.2010
FI07.07.2010
NL07.07.2010
PL07.07.2010
RO07.07.2010
SE07.07.2010
SI07.07.2010
SK07.07.2010
BG07.10.2010
GR08.10.2010
PT08.11.2010
IE07.04.2011
Former [2011/32]AT07.07.2010
CY07.07.2010
CZ07.07.2010
DK07.07.2010
EE07.07.2010
FI07.07.2010
NL07.07.2010
PL07.07.2010
RO07.07.2010
SE07.07.2010
SI07.07.2010
SK07.07.2010
BG07.10.2010
GR08.10.2010
PT08.11.2010
Former [2011/23]AT07.07.2010
CY07.07.2010
CZ07.07.2010
DK07.07.2010
EE07.07.2010
FI07.07.2010
NL07.07.2010
PL07.07.2010
SE07.07.2010
SI07.07.2010
SK07.07.2010
BG07.10.2010
GR08.10.2010
PT08.11.2010
Former [2011/19]AT07.07.2010
CY07.07.2010
DK07.07.2010
FI07.07.2010
NL07.07.2010
PL07.07.2010
SE07.07.2010
SI07.07.2010
BG07.10.2010
GR08.10.2010
PT08.11.2010
Former [2011/15]AT07.07.2010
CY07.07.2010
FI07.07.2010
NL07.07.2010
PL07.07.2010
SE07.07.2010
SI07.07.2010
BG07.10.2010
GR08.10.2010
PT08.11.2010
Former [2011/13]AT07.07.2010
CY07.07.2010
FI07.07.2010
NL07.07.2010
PL07.07.2010
SI07.07.2010
BG07.10.2010
PT08.11.2010
Former [2011/12]AT07.07.2010
FI07.07.2010
NL07.07.2010
PL07.07.2010
SI07.07.2010
BG07.10.2010
PT08.11.2010
Former [2011/10]AT07.07.2010
FI07.07.2010
NL07.07.2010
PL07.07.2010
SI07.07.2010
PT08.11.2010
Former [2011/08]AT07.07.2010
NL07.07.2010
SI07.07.2010
Former [2010/52]SI07.07.2010
Cited inInternational search[Y]WO9951599  (NEUROGEN CORP [US], et al) [Y] 1-36* page 58 - page 64; claims 1-9 *;
 [YD]WO02088095  (GLAXO GROUP LTD [GB], et al) [YD] 1-36 * page 75 - page 81; claims 1-25 *;
 [Y]WO02100863  (GLAXO GROUP LTD [GB], et al) [Y] 1-36 * page 33 - page 35; claims 1-20 *;
 [YD]WO03008412  (GLAXO GROUP LTD [GB], et al) [YD] 1-36 * page 31 - page 34; claims 1-22 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.